Longeveron (LGVN) Net Equity Issued and Repurchased (2020 - 2025)
Longeveron (LGVN) posted quarterly Net Equity Issued and Repurchased of $15.9 million for Q4 2025, up 95.24% quarter-over-quarter from $8.1 million in Q3 2024.
Longeveron (LGVN) Net Equity Issued and Repurchased (2020 - 2025) Analysis & Trends
Longeveron's Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $15.9 million for Q4 2025.
- In Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $15.9 million; the TTM figure through Dec 2025 stood at $28.7 million (up 122.8% YoY), while the FY2025 annual figure was $5.0 million, down 61.29% from the prior year.
- Net Equity Issued and Repurchased for Q4 2025 stood at $15.9 million, up from $8.1 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $26.7 million in Q1 2021, with the low at -$1000.0 in Q4 2021.
- The 3-year median for Net Equity Issued and Repurchased is $6.4 million (2024), against an average of $9.2 million.
- Peak annual rise in Net Equity Issued and Repurchased reached 2326.91% in 2021, while the deepest fall reached 2326.91% in 2021.
- Longeveron's Net Equity Issued and Repurchased stood at -$1000.0 in 2021, then jumped by 814500.0% to $8.1 million in 2024, then surged by 95.24% to $15.9 million in 2025.
- Business Quant data shows LGVN's Net Equity Issued and Repurchased at $15.9 million in Q4 2025, $8.1 million in Q3 2024, and $4.6 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.90 Mn |
| Dec 31, 2025 | 15.90 Mn |
| Sep 30, 2024 | 8.14 Mn |
| Sep 30, 2024 | 8.14 Mn |
| Jun 30, 2024 | 4.62 Mn |
| Jun 30, 2024 | 4.62 Mn |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2021 | -1,000.00 |
| Dec 31, 2021 | -1,000.00 |
| Mar 31, 2021 | 26.70 Mn |
| Mar 31, 2021 | 26.70 Mn |
| Mar 31, 2020 | 1.10 Mn |
| Mar 31, 2020 | 1.10 Mn |